Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Adeno-associated virus Stories

2009-05-28 14:15:00

Phase 1 Data Demonstrate Safety and Evidence of Biological Activity in 9 of 12 Patients; Phase 2 Study Currently Enrolling in 17 Leading U.S. Medical Centers SAN DIEGO, May 28 /PRNewswire/ -- Celladon Corporation presented today Phase 1 data from the Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID), a First-in-Human Phase 1/2 Clinical Trial, in a scientific symposium at the 12th Annual American Society of Gene Therapy Meeting. The Phase 1...

2009-02-17 11:55:21

U.S. scientists have turned a relatively benign virus into an infectious form that, in its first gene therapy test, cured cystic fibrosis tissue in culture. Researchers from the University of California-Berkeley and the University of Iowa said their achievement with the benign adeno-associated virus overcomes a major problem of earlier virus-based gene therapy for cystic fibrosis, setting the stage for tests in advanced animal models of the disease. I think it is worthwhile thinking about...

2009-02-17 10:53:02

Researchers from the University of California, Berkeley, and the University of Iowa have turned a relatively benign virus into a highly infectious form that is ideal as a carrier for gene therapy.In its first gene therapy test, it completely cured human cystic fibrosis lung tissue in culture.This success with the benign adeno-associated virus (AAV), published this week in the online early edition of the journal Proceedings of the National Academy of Sciences, overcomes a major problem of...

2008-10-28 09:00:40

Targeted Genetics Corporation (NASDAQ: TGEN) will report its third quarter 2008 financial results after the close of the financial markets on Wednesday, November 5, 2008. Following the announcement, management will host a conference call and webcast discussion of the financial results and provide a general corporate update beginning at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time. You may access the live webcast via the "Events" section found on the homepage of the Company's website at:...

2008-10-27 09:00:41

Targeted Genetics Corporation (NASDAQ: TGEN) announced positive results of its now completed Phase 1/2 clinical study with the last subject having finished the protocol-required follow-up. The data demonstrated that tgAAC94, an investigational agent designed to inhibit activity of tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation, is well tolerated and may improve disease symptoms in inflammatory arthritis patients. The results of the study were presented yesterday...

2008-09-18 03:00:24

AMSTERDAM, The Netherlands, September 18 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it obtained a license from Amgen to use their GDNF gene for the development of a gene therapy treatment for Parkinson's disease. The combination of this gene with AMT's proprietary adeno-associated virus (AAV) gene therapy platform could potentially allow the development of an effective, long-term treatment for...

2008-09-05 06:00:23

Neurologix, a biotechnology company engaged in the development of gene therapies for the brain and central nervous system, and Aegera Therapeutics, a private clinical stage company focused on oncology and neuropathic pain, have executed an exclusive license agreement. Pursuant to the agreement, Neurologix has exclusively licensed the worldwide rights, excluding China, for the use of the x-linked inhibitor of apoptosis protein (XIAP) gene for therapeutic or prophylactic purposes in the...

2008-09-03 09:00:08

Neurologix, Inc. (OTCBB: NRGX), a biotechnology company engaged in the development of innovative gene therapies for the brain and central nervous system, and Aegera Therapeutics, a private clinical stage company focused on oncology and neuropathic pain, announced today their execution of an exclusive license agreement. Pursuant to the agreement, Neurologix has exclusively licensed the worldwide rights, excluding China, for the use of the XIAP gene (x-linked inhibitor of apoptosis protein) for...

2008-07-29 09:01:15

Targeted Genetics Corporation (NASDAQ: TGEN) will report its second quarter 2008 financial results before the open of the financial markets on Wednesday, August 6, 2008. Following the announcement, management will host a conference call and webcast discussion of the financial results and provide a general corporate update beginning at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time. You may access the live webcast via the "Events" section found on the homepage of the Company's website at:...

1cacc12200dd8d590229b19ac10a835d
2008-05-13 12:55:05

A recent study conducted by US researchers revealed that gene therapy could result in recession of a rare neurological disorder in children.Although lead researcher Dr. Ron Crystal of New York-Presbyterian Hospital/Weill Cornell Medical Center said the team of researchers was "encouraged by the study's results. "It's not a cure."Late infantile neuronal ceroidlipofuscinosis, or LINCL, is a neurodegenerative disease that affects the central nervous system in children. The disease usually...